Matthew Korenberg - 01 Nov 2022 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
President & COO
Signature
/s/ Andrew Reardon, Attorney-in-Fact for Matthew E. Korenberg
Issuer symbol
LGND
Transactions as of
01 Nov 2022
Transactions value $
$0
Form type
4
Filing time
03 Nov 2022, 21:10:22 UTC
Previous filing
04 Aug 2022
Next filing
01 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Award $0 +27,714 +47.53% $0 86,021 01 Nov 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 19,258 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and does not expire.
F2 Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the OmniAb, Inc. from the Issuer on November 1, 2022.

Remarks:

Exhibit 24 - Power of Attorney.